TG Therapeutics Inc. (NASDAQ: TGTX) closed the day trading at $18.48 up 6.45% from the previous closing price of $17.36. In other words, the price has increased by $+1.12 from its previous closing price. On the day, 4006271 shares were traded. TGTX stock price reached its highest trading level at $18.68 during the session, while it also had its lowest trading level at $16.93.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
For a better understanding of TGTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.00 and its Current Ratio is at 5.00. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 20, 2022, initiated with a Underperform rating and assigned the stock a target price of $5.
On February 23, 2022, B. Riley Securities reiterated its Buy rating and also upped its target price recommendation from $49 to $35.
Goldman Downgraded its Neutral to Sell on November 15, 2021, whereas the target price for the stock was revised from $33 to $26.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 06 when Echelard Yann bought 9,000 shares for $10.64 per share. The transaction valued at 95,760 led to the insider holds 201,848 shares of the business.
Charney Laurence N sold 30,000 shares of TGTX for $333,000 on Jan 04. The Director now owns 234,729 shares after completing the transaction at $11.10 per share.
For the stock, the TTM Price-to-Sale (P/S) ratio is 556.06 while its Price-to-Book (P/B) ratio in mrq is 24.97.
Stock Price History:
Over the past 52 weeks, TGTX has reached a high of $18.31, while it has fallen to a 52-week low of $3.48. The 50-Day Moving Average of the stock is 10.98, while the 200-Day Moving Average is calculated to be 7.36.
Over the past 3-months, TGTX traded about 5.54M shares per day on average, while over the past 10 days, TGTX traded about 5.05M shares per day. A total of 135.33M shares are outstanding, with a floating share count of 133.34M. Insiders hold about 1.10% of the company’s shares, while institutions hold 69.70% stake in the company. Shares short for TGTX as of Oct 13, 2022 were 19.44M with a Short Ratio of 22.56M, compared to 17.71M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 13.38% and a Short% of Float of 17.23%.
Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.47, while EPS last year was -$0.65. The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.34 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$0.91 and -$1.77 for the fiscal current year, implying an average EPS of -$1.5. EPS for the following year is -$1.19, with 8 analysts recommending between -$0.83 and -$1.48.
A total of 6 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $57.68M, while the lowest revenue estimate was $2.69M, resulting in an average revenue estimate of $14.01M. In the same quarter a year ago, actual revenue was $6.69M, up 109.40% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $79.05M in the next fiscal year. The high estimate is $163.8M and the low estimate is $42.31M. The average revenue growth estimate for next year is up 464.20% from the average revenue estimate for this year.